Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Nov 17;13(22):5750.
doi: 10.3390/cancers13225750.

Next-Generation Sequencing Targeted Panel in Routine Care for Metastatic Colon Cancers

Arnaud Bayle  1 , Debora Basile  1 , Simon Garinet  2   3 , Bastien Rance  4 , Pierre Laurent-Puig  2   3 , Hélène Blons  2   3 , Julien Taieb  1   3 , Geraldine Perkins  1   3
Affiliations

Next-Generation Sequencing Targeted Panel in Routine Care for Metastatic Colon Cancers

Arnaud Bayle et al. Cancers (Basel). .

Abstract

In digestive oncology, the clinical impact of targeted next-generation sequencing (NGS) in routine practice should be addressed. In this work, we studied the impact of a 22-gene NGS amplicon-based panel with Ion Torrent Proton Sequencing, prospectively performed in routine practice. We analyzed the results of extended molecular testing, beyond RAS and BRAF, in metastatic colorectal cancer (mCRC) patients in a single-center, retrospective, observational study of consecutive mCRC patients followed up at the Georges Pompidou European Hospital between January 2016 and December 2018. Overall, 210 patients with mCRC were included. Median follow-up was 25.4 months (IQR: 14.9-39.5). The three most frequently mutated genes were: TP53 (63%), KRAS (41%) and PIK3CA (19%). A positive association was found between overall survival and performance status (PS) ≥ 2 (HR: 4.91 (1.84-13.1); p = 0.001) and differentiation (HR: 4.70 (1.51-14.6); p = 0.007) in multivariate analysis. The NGS panel enabled five patients to access a targeted therapy not currently registered for CRC. In conclusion, targeted NGS panels in mCRC are feasible in routine practice, but need to be regularly updated and in-depth studies are needed to better analyze the prognostic factors.

Keywords: colon cancer; digestive cancer; genomics; next-generation sequencing; oncology.

PubMed Disclaimer

Conflict of interest statement

J.T. has received honoraria as a speaker and/or in an advisory role from Merck KGaA, Sanofi, Roche Genentech, M.S.D., Astra Zeneca, Servier, Novartis, Pierre Fabre, HallioDx and Amgen. P.L.-P. has received honoraria as a speaker and/or in an advisory role from Sanofi, Roche, M.S.D., Astra Zeneca, Servier, Pierre Fabre Merck KGaA, Amgen, Biocartis. H.B. has received honoraria as a speaker and/or in an advisory role from Takeda, M.S.D., Astra Zeneca. G.P. received a grant from Merck Serono, reports honoraria from Servier and Sanofi. The other authors have no conflicts of interest to disclose.

Figures

Figure 1
Figure 1
Flowchart.
Figure 2
Figure 2
Major molecular abnormalities in digestive cancers and current treatment options.
See this image and copyright information in PMC

References

    1. Slatko B.E., Gardner A.F., Ausubel F.M. Overview of Next Generation Sequencing Technologies. Curr. Protoc. Mol. Biol. 2018;122:e59. doi: 10.1002/cpmb.59. - DOI - PMC - PubMed
    1. Colomer R., Mondejar R., Romero-Laorden N., Alfranca A., Sanchez-Madrid F., Quintela-Fandino M. When Should We Order a next Generation Sequencing Test in a Patient with Cancer? EClinicalMedicine. 2020;25:100487. doi: 10.1016/j.eclinm.2020.100487. - DOI - PMC - PubMed
    1. Yohe S., Thyagarajan B. Review of Clinical Next-Generation Sequencing. Arch. Pathol. Lab. Med. 2017;141:1544–1557. doi: 10.5858/arpa.2016-0501-RA. - DOI - PubMed
    1. Kulski J.K. Next-Generation Sequencing—An Overview of the History, Tools, and “Omic” Applications. IntechOpen; London, UK: 2016.
    1. Global Cancer Observatory. [(accessed on 11 September 2020)]. Available online: https://gco.iarc.fr/